|Back to Search|
|Clinical Study ID||
|Study Title||A phase III, double-blinded, randomized, multicenter, clinical study to assess the safety and immunogenicity of GSK Biologicals' Tdap 0.3 mg candidate vaccine when given as a booster dose to healthy school children and adolescents (9-13 years of age), previously vaccinated with a 5th consecutive dose of acellular pertussis-containing vaccine, in studies APV-118 or APV-120|
|Patient Level Data||Study Listed on ClinicalStudyDataRequest.com|
|Study Recruitment Status||Completed|
|Generic Name||Combined Reduced Antigen Content Diphtheria, Tetanus, Acellular Pertussis Vaccine|
|Study Indication||Acellular Pertussis; Diphtheria; Tetanus; acellular pertussis|
For more information on this register please email GSKClinicalSupportHD@gsk.com
GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.
IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).
This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.
EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.